GVR Report cover Alopecia Market Size, Share & Trends Report

Alopecia Market Size, Share & Trends Analysis Report By Disease Type (Alopecia Areata, Cicatricial, Traction, Androgenetic Alopecia), By Treatment, By Gender, By Sales Channel, By End-use, By Region, And Segment Forecasts, 2021 - 2028

  • Report ID: 978-1-68038-856-5
  • Number of Pages: 120
  • Format: Electronic (PDF)
  • Historical Range: 2017 - 2019
  • Industry: Healthcare

Report Overview

The global alopecia market size was valued at USD 7.6 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 8.1% from 2021 to 2028. The increasing prevalence of hair loss, technological advancements in alopecia treatment, and the rise in prevalence of chronic diseases that are associated with hair loss are some of the major factors driving the market. According to data published by the American Hair Loss Association, it was stated that over 95.0% of hair loss in men is caused due to androgenetic alopecia. Similarly, data published by the International Society of Hair Restoration Surgery estimated that nearly 40.0% of men encounter some degree of hair loss by 35 years of age, 65.0% at 60 years, 70.0% at 80 years, and 80.0% at the age of 85.

U.K. alopecia market size, by disease type, 2017 - 2028 (USD Million)

An increase in the number of initiatives being undertaken by organizations, such as the National Alopecia Areata Foundation and the American Hair Loss Association, for spreading awareness about hair regrowth and available treatment options are leading to an increase in healthcare expenditure. The Affordable Care Act of 2010 provides people with affordable access to healthcare insurance, thus providing benefits to economically weaker patients. This results in an overall increase in the treatment rate, which is expected to fuel the growth of the market. Furthermore, increasing awareness regarding hair loss is increasing the demand for pain-less therapy with minimal side effects is fueling the treatment rate globally.

The growing prevalence of hair loss is one of the major factors driving the market growth. According to the American Academy of Dermatology Association (AAD), about 50 million men and 30 million women were estimated to be affected by some form of alopecia in the U.S. in 2018. According to data published by the Journal of Clinical and Diagnostic Research (JCDR), around 60% of the population has hair thinning problems and pattern hair loss is the most common form of hair loss in both males and females. Moreover, around 2% of the population is at risk of developing AA in their lifetime globally, irrespective of gender.

Major buyers of the market are patients suffering from alopecia and dermatological clinics. Moderate to the high bargaining power of buyers can be attributed to the availability of traditional medicines and cosmetic products, such as hair growth serums. As most treatment options are available off-label and in generic form, there is a variety of options to choose from. This, in turn, is expected to boost the bargaining power of buyers during the forecast period. Moreover, the threat of substitutes is expected to remain high during the forecast period. Primary substitutes to the market are wigs, hairpieces, and hair restoration and transplants. Availability of traditional medicines, herbal and cosmetic products coupled with nutritional supplements, such as biotin-based gummies, also negatively impacts market growth. Due to the uncertainty of treatment, several patients opt for substitutes. Moreover, the absence of approved treatment further limits the adoption of alopecia therapeutics.

Disease Type Insights

The alopecia areata segment dominated the market and held the largest revenue share of 35.2% in 2020 driven by high disease prevalence and growing consumer awareness among patients. According to National Alopecia Areata Foundation, around 147.0 million people are affected by AA globally, out of this, around 6.8 million people live in the U.S. only. The segment is anticipated to witness a significant growth rate over the forecast period owing to an increase in the development of novel therapy and favorable initiatives in the approval process. For instance, in March 2020, Incyte Corporation and Eli Lilly and Company received the Breakthrough Therapy Designation for baricitinib for the treatment of AA by the U.S. FDA. The Breakthrough Therapy Designation will help to get approval earlier.

The androgenetic alopecia segment and held the second-largest revenue share in 2020. The rising awareness about these conditions, driven by proactive initiatives by organizations such as American Hair Loss Association, Alopecia World and National Hair Loss Awareness Month by HairMax (Lexington International) are contributing to the market growth. Moreover, the adoption of laser-based treatment options for AGA is also fueling the market growth over the forecast period. The companies such as LUTRONIC, iRestore Hair Growth System (Freedom Laser Therapy), Lexington Intl., LLC. (HairMax) are proving the innovative and painless treatment options for treat AGA.

Alopecia totalis and alopecia universalis segments are anticipated to grow at the fastest growth rate over the forecast period. Increasing awareness regarding severe forms of alopecia and an increase in research activities to develop novel and effective treatment options is expected to drive the market growth over the forecast period. According to the Genetic and Rare Diseases Information Center (GARD), around 7% to 25% of people suffering from AA develop alopecia totalis and alopecia universalis. Moreover, the presence of pipeline drugs such as baricitinib, deuruxolitinib, and ritlecitinib for the treatment of severe conditions of AA is expected to propel the segment growth over the forecast period.

Treatment Type Insights

The pharmaceutical segment dominated the market and accounted for the largest revenue share of more than 98.0% in 2020. The low cost of pharmaceutical products and high usage of prescription and OTC drugs are the main factors driving the segment. Finasteride and minoxidil are the most common drugs used to treat any form of alopecia. Finasteride and minoxidil are the only U.S.-approved drugs for the treatment of both Female Pattern Hair Loss (FPHL) and as well as Male Pattern Hair Loss (MPHL). Moreover, major pharmaceutical companies such as Lilly, Pfizer Inc., Concert Pharmaceuticals are actively involved in the development of novel drugs to treat alopecia, which is anticipated to drive the segment over the forecast period.

Devices consist of laser-based device used for hair regrowth and are expected to grow at the fastest growth rate during the forecast period. Increasing adoption of painless treatment coupled with minimal side effects and adoption of home-used laser devices are forces driving the segment growth in the next 5 to 8 years. Low-level laser therapy offers the convenience of at-home use and minimizes the need for clinical visits. Moreover, it provides a non-pharmacological and non-surgical viable therapeutic action for hair restoration due to which the market is expected to grow steadily over the forecast period. FDA clearance for low-level laser therapy devices, such as iRestore and Hairmax, for treatment of most commonly occurring forms of alopecia, such as the androgenetic alopecia, is likely to boost the market growth for the same over the forecast period.

End-use Insights

The dermatology segment dominated the market and accounted for the largest revenue share of 57.6% over the forecast period. Modern treatment methods such as laser technology, a strong product pipeline, and heightened consumer awareness regarding the use of prescription medicines are the main factors responsible for the continued growth of the segment. Given the consulting dermatologist’s ability to provide appropriate customized medications or therapy that yield effective results, they are often considered the preferred option for the treatment of alopecia.

The home care setting segment will be the fastest-growing segment over the forecast period owing to convenience, ease of usage, and patient comfort. Moreover, there are a growing number of regulatory approvals being given for home-use devices in addition to the growing adoption of non-invasive procedures such as laser therapy that do not require any lifestyle changes. For instance, in March 2020, the U.S. FDA approved LifeMD’s Shapiro MD hair restoration device to promote hair growth in men and women with androgenetic alopecia and available through direct-to-consumer platforms and telemedicine.

Gender Insights

The male alopecia segment dominated the market and accounted for the largest revenue share of 53.8% in 2020 owing to the high prevalence of hair loss in the male population worldwide. Androgenetic alopecia is the most common alopecia in the male population. It is estimated that approximately 50 percent of men experience some degree of hair loss at an average age of 50 with over 95% of cases being the androgenetic type. Moreover, factors such as the increased amount of tobacco intake in men and a rising geriatric population, are expected to further propel the market over the forecast period.

However, the female alopecia market is anticipated to grow at the fastest rate over the forecast period. Rising awareness levels, lifestyle changes, increased PCOS levels and a growing trend of cosmetic procedures are expected to increase the growth of the market.

Sales Channel Insights

The prescription segment dominated the market and accounted for the largest revenue share of 64.9% in 2020 due to the high number of visits to dermatologists for hair loss treatment. According to the National Library of Medicine, around 2.6 million outpatients visit dermatologists for alopecia areata treatment in the U.S. annually. Moreover, a strong product pipeline, growing disposable incomes, and rising prevalence of chronic diseases which ultimately lead to hair loss are expected to drive the segment growth at the fastest rate over the forecast period.

Global alopecia market share, by sales channel, 2020 (%)

Whereas, the market is being further driven by the OTC segment which is widely used in the developing regions where players find multiple opportunities to address unmet medical needs of a large patient pool across countries such as China, Japan, Mexico, Brazil, and India. Moreover, OTC drugs remain the preferred choice of medication amongst males suffering from androgenetic alopecia and for other types of hair loss conditions where there is a lack of approved drugs, leading consumers to rely on off-label or OTC drugs.

Regional Insights

North America dominated the market and accounted for the largest revenue share of 36.3% in 2020. The growth is driven by high disease prevalence, rising consumer awareness, proactive government measures, technological advancements, and improvements in healthcare infrastructure. The presence of key players in this region is a key propeller of market growth. Moreover, increasing the adoption of laser-based therapy to treat alopecia is also increasing the treatment rate in the region. Moreover, the presence of government and non-profit organizations such as the National Alopecia Areata Foundation (NAAF), Canadian Alopecia Areata Foundation, and others provide guidelines and create awareness among people, is likely to have a positive impact on the market.

In Asia Pacific, the market is estimated to witness the highest CAGR over the forecast period due to an increase in penetration of alopecia products, rising disposable income, and rising consumer awareness. Moreover, improving the healthcare regulatory scenario in developing countries is expected to attract international players to invest and capitalize on the available market opportunities. For instance, in 2016, China regulatory authority, China Food and Drug Administration, approved the iGrow laser system by Apira Science and became the first-ever laser-based hair growth device to be approved in China.

Europe is also anticipated to command a significant market share during the forecast period. This growth can be attributed to several factors, such as technological advancements and awareness campaigns organized by public and private groups. The European Hair Research Society plays an important role in conducting campaigns related to hair loss research and awareness related to effective treatment to prevent hair loss.

Key Companies & Market Share Insights

Some of the key players that dominated the global pharmaceutical market for alopecia in 2020 include Johnson & Johnson Services, Inc.; Merck & Co., Inc.; Cipla Limited; Sun Pharmaceuticals Industries Ltd.; Dr. Reddy’s Laboratories Ltd.; GlaxoSmithKline plc; Aurobindo Pharma; Mylan N.V. (Viatris Inc.). While some of the prominent players in the devices market include:

  • iRestore Hair Growth System (Freedom Laser Therapy)

  • iGrow Laser (Apira Science, Inc)

  • Theradome

  • Curallux, LLC (Capillus)


  • Lexington Intl., LLC. (HairMax)

Alopecia Market Report Scope 

Report Attribute


Market size value in 2021

USD 7.8 billion

Revenue forecast in 2028

USD 14.2 billion

Growth rate

CAGR of 8.1% from 2021 to 2028

Base year for estimation


Historical data

2017 - 2019

Forecast period

2021 - 2028

Quantitative units

Revenue in USD million and CAGR from 2021 to 2028

Report coverage

Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Segments covered

Disease type, treatment, gender, sales channel, end-use, region

Regional scope

North America; Europe; Asia Pacific; Latin America; MEA

Country scope

U.S.; Canada; U.K.; Germany; Spain; France; Italy; India; China; Japan; Australia; South Korea; Brazil; Mexico; Saudi Arabia; South Africa

Key Pharmaceutical companies profiled

Johnson & Johnson Services, Inc.; Merck & Co. Inc.; Cipla Limited; Sun Pharmaceuticals Industries Ltd.; Dr. Reddy's Laboratories Ltd.; GlaxoSmithKline plc.; Aurobindo Pharma; Mylan N.V. (Viatris Inc.)

Key Laser Device Manufacturers profiled

Freedom Laser Therapy; Apira Science, Inc; Theradome; Theradome; LUTRONIC; Lexington Intl., LLC

Customization scope

Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope.

Pricing and purchase options

Avail customized purchase options to meet your exact research needs. Explore purchase options

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2028. For the purpose of this study, Grand View Research has segmented the global alopecia market report on the basis of treatment, disease type, gender, sales channel, end-use, and region:

  • Disease Type Outlook (Revenue, USD Million, 2017 - 2028)

    • Alopecia Areata

      • Male

      • Female

    • Cicatricial Alopecia

      • Male

      • Female

    • Traction Alopecia

      • Male

      • Female

    • Alopecia Totalis

      • Male

      • Female

    • Alopecia Universalis

      • Male

      • Female

    • Androgenetic Alopecia

      • Male

      • Female

    • Others

      • Male

      • Female

  • Treatment Outlook (Revenue, USD Million, 2017 - 2028)

    • Pharmaceuticals

    • Devices

  • Gender Outlook (Revenue, USD Million, 2017 - 2028)

    • Male

    • Female

  • Sales Channel Outlook (Revenue, USD Million, 2017 - 2028)

    • Prescriptions

    • OTC

  • End Use Outlook (Revenue, USD Million, 2017 - 2028)

    • Homecare Settings

    • Dermatology Clinics

  • Regional Outlook (Revenue, USD Million, 2017 - 2028)

    • North America

      • U.S.

      • Canada

    • Europe

      • U.K.

      • Germany

      • Spain

      • France

      • Italy

    • Asia Pacific

      • Japan

      • China

      • India

      • South Korea

      • Australia

    • Latin America

      • Brazil

      • Mexico

    • Middle East & Africa

      • South Africa

      • Saudi Arabia

Frequently Asked Questions About This Report

gvr icn


gvr icn

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

gvr icn


We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

esomar icon

ESOMAR certified & member

D&B icon

Leading SME award by D&B

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.

great place to work icon